R&D Paving the road to functionally active antibody drugs Antibody drugs have reshaped how we treat diseases.
R&D Prediction is very difficult, especially if it’s about the f... In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Carl Hansen, CEO of AbCellera, for a conversation on the discovery and acceleration of antibody therapeutics.
News Regeneron's Inmazeb named Galien's Best Biotech Product The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
